Balaxi (BALAXI) | Stock Overview & Key Data
Balaxi Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹216.04 on October 12, 2020
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Balaxi
BALAXI
|
1.49B Small-cap | -2.90% | -8.08% | 34.63% | -18.08% | -15.91% | -56.05% | -78.64% | -80.93% | 376.04% | 661.67% | 661.67% |
|
Biocon
BIOCON
|
566.52B Large-cap | 1.66% | -3.27% | 10.34% | 6.50% | 7.30% | 17.90% | 71.09% | 5.03% | 250.57% | 603.49% | 1,357.39% |
|
OneSource Specialty
ONESOURCE
|
202.76B Large-cap | -6.58% | -11.52% | 8.72% | 0.44% | -9.19% | -20.38% | -5.70% | -5.70% | -5.70% | -5.70% | -5.70% |
|
Zota Health Care
ZOTA
|
39.41B Small-cap | 3.68% | 3.22% | 14.06% | -26.10% | -17.99% | 27.17% | 243.00% | 632.12% | 1,248.00% | 1,248.00% | 1,248.00% |
|
Dishman Carbogen
DCAL
|
26.50B Small-cap | -2.24% | -7.21% | 9.02% | -19.76% | -29.73% | -33.95% | 46.77% | -6.77% | 33.46% | 290.77% | 118.12% |
|
Panacea Biotec
PANACEABIO
|
21.84B Small-cap | -2.19% | 39.94% | 70.71% | 51.42% | 43.20% | 18.85% | 307.76% | 44.67% | 440.21% | 276.43% | 141.23% |
Ownership & Short Interest
Calculate Your Balaxi Investment Returns
Long-Term Investment Performance Analysis
Balaxi stock price in Jul 2016 was ₹4.18, A ₹1,000.00 lump sum investment in Balaxi made 9 years ago would be worth approximately ₹5,691.39 today, representing a exceptional return of 469.14%. This translates to an annualized return (CAGR) of 19.18%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BALAXI's 52-week high and low?
- In the last 52 weeks, Balaxi reached a high of ₹54.70 (on June 27, 2025) and a low of ₹15.20 (on March 27, 2026).
- What is the market cap and P/E ratio for BALAXI?
- Curious about Balaxi's size and valuation? Its market capitalization stands at 1.49B. When it comes to valuation, the P/E ratio (trailing twelve months) is 15.75, and the forward P/E (looking ahead) is N/A.
- Does BALAXI pay dividends? If so, what's the yield?
- As for dividends, Balaxi isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Balaxi's main competitors or similar companies to consider before investing?
When looking at Balaxi, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON566.52B Healthcare Biotechnology 17.90% 71.09% OneSource Specialty
ONESOURCE202.76B Healthcare Biotechnology -20.38% -5.70% Zota Health Care
ZOTA39.41B Healthcare Biotechnology 27.17% 243.00% Dishman Carbogen
DCAL26.50B Healthcare Biotechnology -33.95% 46.77% Panacea Biotec
PANACEABIO21.84B Healthcare Biotechnology 18.85% 307.76% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Balaxi Pharmaceuticals Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Balaxi's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.82%, the Debt to Equity ratio from the most recent quarter is 23.75, and its Gross Profit Margin stands at 42.47%.
- What is the recent revenue and earnings growth for BALAXI?
- Looking at Balaxi's growth, its revenue over the trailing twelve months (TTM) was INR3B. Compared to the same quarter last year (YoY), quarterly revenue grew by -1.00%, and quarterly earnings saw a YoY growth of -94.30%.
- How much of BALAXI stock is held by insiders and institutions?
- Wondering who owns Balaxi stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.